Clinical

Researchers at the Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, have reported that outcome measures for future clinical trials should include evaluations… Read More »Outcome measures for future trials for autosomal dominant vitelliform macular dystrophy caused by BEST1 mutations.

Researchers at the UCL Institute of Ophthalmology, London and Moorfields Eye Hospital NHS Foundation Trust has reported a novel history of RP2 mutations arising from… Read More »A natural history of XLRP from RP2 mutations aim to facilitate trial endpoints for future clinical studies.